Pharmacological modulation of dietary lipid-induced cerebral capillary dysfunction: Considerations for reducing risk for Alzheimer's disease

• Published in: Critical reviews in clinical laboratory sciences Vol. 53; no. 3; pp. 166 - 183
• Main Authors: Pallebage-Gamarallage, Menuka, Takechi, Ryusuke, Lam, Virginie, Elahy, Mina, Mamo, John
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 03.05.2016; Taylor & Francis Ltd
• Subjects: Alzheimer Disease - drug therapy; Alzheimer Disease - physiopathology; Alzheimer's disease; Animals; Anti-Inflammatory Agents - therapeutic use; Atherogenic fats; beta-amyloid; blood-brain barrier; Brain - blood supply; Brain - physiopathology; Capillaries - physiopathology; capillary vasodilation; Dietary Fats - adverse effects; Homeostasis; Humans; lipid-lowering agents; Lipids; Neurology; neurovascular inflammation; Pathology; Pharmacology; Protein synthesis; redox homeostasis; Risk Reduction Behavior; beta-amyloid; blood–brain barrier; capillary vasodilation; Atherogenic fats; redox homeostasis; lipid-lowering agents; neurovascular inflammation
• DOI: 10.3109/10408363.2015.1115820
• ISSN: 1040-8363

An increasing body of evidence suggests that cerebrovascular dysfunction and microvessel disease precede the evolution of hallmark pathological features that characterise Alzheimer's disease (AD), consistent with a causal association for onset or progression. Recent studies, principally in genetically unmanipulated animal models, suggest that chronic ingestion of diets enriched in saturated fats and cholesterol may compromise blood-brain barrier (BBB) integrity resulting in inappropriate blood-to-brain extravasation of plasma proteins, including lipid macromolecules that may be enriched in amyloid-β (Aβ). Brain parenchymal retention of blood proteins and lipoprotein bound Aβ is associated with heightened neurovascular inflammation, altered redox homeostasis and nitric oxide (NO) metabolism. Therefore, it is a reasonable proposition that lipid-lowering agents may positively modulate BBB integrity and by extension attenuate risk or progression of AD. In addition to their robust lipid lowering properties, reported beneficial effects of lipid-lowering agents were attributed to their pleiotropic properties via modulation of inflammation, oxidative stress, NO and Aβ metabolism. The review is a contemporary consideration of a complex body of literature intended to synthesise focussed consideration of mechanisms central to regulation of BBB function and integrity. Emphasis is given to dietary fat driven significant epidemiological evidence consistent with heightened risk amongst populations consuming greater amounts of saturated fats and cholesterol. In addition, potential neurovascular benefits associated with the use of hypolipidemic statins, probucol and fenofibrate are also presented in the context of lipid-lowering and pleiotropic properties.